Breast cancer (BC) is the most frequent cancer diagnosed in women worldwide. This
heterogeneous disease can be classified into four molecular subtypes (luminal A, luminal B …

Cancer cells undergo metabolic reprogramming and switch to a 'glycolysis-
dominant'metabolic profile to promote their survival and meet their requirements for energy …

PURPOSE Hormone receptor–positive (HR+) human epidermal growth factor receptor 2–
negative (HER2–) endocrine-resistant metastatic breast cancer is treated with sequential …

Ziele Das Ziel dieser offiziellen Leitlinie, die von der Deutschen Gesellschaft für
Gynäkologie und Geburtshilfe (DGGG) und der Deutschen Krebsgesellschaft (DKG) …

Summary Background Alpelisib, a PI3Kα-selective inhibitor and degrader, plus fulvestrant
showed efficacy in hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced …

PURPOSE To update recommendations of the ASCO systemic therapy for hormone receptor
(HR)-positive metastatic breast cancer (MBC) guideline. METHODS An Expert Panel …

Background PIK3CA mutations occur in approximately 40% of patients with hormone
receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast …

Dysregulated cellular proliferation represents a hallmark feature across all cancers. Aberrant
activation of the cyclin-dependent kinase 4 and 6 (CDK4/6) pathway, independent of …

Background An earlier analysis of this phase 3 trial showed that the addition of a cyclin-
dependent kinase 4 and 6 (CDK4/6) inhibitor to endocrine therapy provided a greater …

Background The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib, in
combination with fulvestrant therapy, prolongs progression-free survival among patients with …